<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pituitary and adrenal gland dysfunction in patients with HIV</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pituitary and adrenal gland dysfunction in patients with HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pituitary and adrenal gland dysfunction in patients with HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melissa Weinberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morris Schambelan, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rajesh T Gandhi, MD, FIDSA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In the early acquired immunodeficiency syndrome (AIDS) epidemic, the diverse endocrine manifestations of human immunodeficiency virus (HIV) infection were more often a consequence of opportunistic infections, neoplasms, or concomitant systemic illness. The widespread use of potent antiretroviral therapy has led to a decline in the incidence of glandular infiltration by opportunistic infections and neoplasms and has generated increased attention toward the metabolic complications of HIV therapy, including insulin resistance, dyslipidemia, and alterations in body fat distribution.</p><p>This topic review will address the assessment and management of pituitary and adrenal disorders in patients with HIV. Issues related to HIV lipodystrophy including metabolic syndrome, bone and calcium disorders, and thyroid dysfunction in this population are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3733.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy"</a> and  <a class="medical medical_review" href="/d/html/3700.html" rel="external">"Treatment of HIV-associated lipodystrophy"</a> and  <a class="medical medical_review" href="/d/html/3738.html" rel="external">"Bone and calcium disorders in patients with HIV"</a> and  <a class="medical medical_review" href="/d/html/3744.html" rel="external">"Thyroid gland dysfunction in the patient with HIV"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>In general, the diagnosis and treatment of a specific endocrinopathy in a patient with HIV infection does not differ from that in an immunocompetent individual. There are, however, some special considerations. HIV infection may cause changes in pituitary and adrenal function that are adaptive and do not require treatment. Furthermore, many of the signs and symptoms of pituitary and adrenal dysfunction are nonspecific and can overlap with other non-endocrine disorders that are common in with HIV. Finally, many medications that are used to treat HIV infection and its complications can induce endocrine dysfunction  (<a class="graphic graphic_table graphicRef83250" href="/d/graphic/83250.html" rel="external">table 1</a>), including affecting pituitary and adrenal hormones.</p><p class="headingAnchor" id="H3"><span class="h1">OPPORTUNISTIC INFECTIONS AND CANCERS</span><span class="headingEndMark"> — </span>In the era of potent antiretroviral therapy (ART), infections and malignancies (ie, Kaposi sarcoma and lymphoma) in the adrenal and pituitary glands are rare in patients with HIV though they may be observed in patients not receiving ART and those with antiretroviral drug-resistant infection  (<a class="graphic graphic_table graphicRef72716" href="/d/graphic/72716.html" rel="external">table 2</a>).</p><p>Tissue is generally required for a definitive diagnosis. When technically feasible, fine-needle aspiration (FNA) biopsy of the adrenal gland provides a less invasive alternative to open biopsy. Pheochromocytoma must always be excluded before FNA biopsy of the adrenal gland is performed. Standard functional testing should also be performed since clinically significant endocrine dysfunction may accompany glandular infection or infiltration of the pituitary or adrenal glands.</p><p class="headingAnchor" id="H4"><span class="h1">PITUITARY GLAND</span><span class="headingEndMark"> — </span>The pituitary gland secretes and releases hormones that directly affect the functions of the thyroid gland, the adrenal gland, and the gonads as well as influencing growth, milk production, and water balance. (See  <a class="medical medical_review" href="/d/html/6628.html" rel="external">"Hypothalamic-pituitary axis"</a> and  <a class="medical medical_review" href="/d/html/6636.html" rel="external">"Causes of hypopituitarism"</a>.)</p><p>The specific effects of HIV infection on pituitary function are discussed below.</p><p class="headingAnchor" id="H5"><span class="h2">Alterations in pituitary function</span><span class="headingEndMark"> — </span>Anterior pituitary functional reserve is usually maintained, as evidenced by studies administering hypothalamic releasing hormones (ie, gonadotropin-, thyrotropin-, and corticotrophin-releasing hormones) to patients with HIV at various stages of illness [<a href="#rid1">1-3</a>]. Post-stimulation peak levels of growth hormone (GH), prolactin, thyroid-stimulating hormone (TSH), and adrenocorticotropic hormone (ACTH) may even be modestly increased, suggesting enhanced pituitary responsiveness due to subclinical target organ dysfunction [<a href="#rid4">4</a>].</p><p>Despite the normal response to gonadotropin-releasing hormone (GnRH), which excludes significant follicle-stimulating hormone (FSH) or luteinizing hormone (LH) deficiency, hypogonadotropic hypogonadism is commonly observed in patients with AIDS [<a href="#rid5">5</a>] as a consequence of hypothalamic dysfunction. This abnormality is likely due to a variety of factors, including the presence of chronic systemic illness, which suppresses the hypothalamic-pituitary-gonadal axis.</p><p>Published reports have demonstrated conflicting results as to whether or not prolactin levels are increased compared with HIV-seronegative controls [<a href="#rid1">1,6-9</a>]. In a large study of 192 clinically stable HIV-infected men, 21 percent were found to have hyperprolactinemia [<a href="#rid10">10</a>]. Although there was no HIV-seronegative control group in this study, this prevalence is greater than would be expected in the general population. The cause for elevations in prolactin is unknown but is hypothesized to be related to immunologic dysregulation. Other researchers have suggested that these higher serum prolactin levels are due to increases in macroprolactin, a glycosylated isoform of prolactin that is not biologically significant [<a href="#rid11">11</a>].</p><p>In contrast to the anterior pituitary gland, posterior pituitary function is often abnormal in patients with AIDS. In a study of 103 hospitalized AIDS patients, 36 were found to have serum sodium less than 130 mEq/L [<a href="#rid12">12</a>]. Hyponatremia was attributed to the syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH) in 23 subjects. There was no definitive evidence, however, of a primary pituitary disorder since there were other confounding factors, including pulmonary infection (most notably <em>Pneumocystis </em>pneumonia) and treatment with medications known to affect fluid and electrolyte metabolism (eg, <a class="drug drug_general" data-topicid="10024" href="/d/drug information/10024.html" rel="external">trimethoprim</a>). (See  <a class="medical medical_review" href="/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)"</a> and  <a class="medical medical_review" href="/d/html/2374.html" rel="external">"Causes of hypotonic hyponatremia in adults"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">The somatotropic axis</span><span class="headingEndMark"> — </span>HIV infection itself does not affect circadian GH secretion, as evidenced by frequent sampling studies among men with asymptomatic HIV infection and clinically stable AIDS [<a href="#rid13">13</a>]. The somatotropic axis, however, is influenced by nutritional status and body composition, leading to characteristic abnormalities in patients with AIDS wasting and the HIV-associated lipodystrophy syndrome  (<a class="graphic graphic_table graphicRef75394" href="/d/graphic/75394.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/3733.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy"</a>.)</p><p class="headingAnchor" id="H1246149509"><span class="h3">HIV-associated lipodystrophy</span><span class="headingEndMark"> — </span>In HIV-associated lipodystrophy, normal GH pulse frequency and insulin-like growth factor (IGF)-1 levels are observed, but there are lower mean GH concentrations, basal GH concentrations, and GH pulse amplitude [<a href="#rid14">14</a>]. Reduced GH levels are inversely correlated with visceral obesity in HIV lipodystrophy [<a href="#rid14">14</a>]. Abnormal response rates to GH stimulation testing with growth hormone releasing hormone (GHRH)-arginine are common [<a href="#rid15">15</a>], with up to one-third demonstrating biochemical GH deficiency (GHD) [<a href="#rid16">16</a>]. The clinical significance of this GHD, however, remains unclear and is less severe than that in patients affected by a true GHD secondary to pituitary disease [<a href="#rid17">17</a>]. Men with HIV demonstrate biochemical GHD more frequently than women, which has been attributed to differences in adipose tissue distribution [<a href="#rid18">18</a>]. Reduced GH levels are also found in generalized obesity. <a class="drug drug_general" data-topicid="16092" href="/d/drug information/16092.html" rel="external">Tesamorelin</a>, a GHRH agonist, is one of several treatments available for the reduction of excess abdominal fat in patients with HIV with lipodystrophy. (See  <a class="medical medical_review" href="/d/html/3733.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy"</a> and  <a class="medical medical_review" href="/d/html/3700.html" rel="external">"Treatment of HIV-associated lipodystrophy", section on 'Fat accumulation'</a>.)</p><p class="headingAnchor" id="H776912201"><span class="h3">AIDS wasting</span><span class="headingEndMark"> — </span>AIDS wasting appears to be associated with an acquired GH-resistant state, with decreased levels of IGF-1 and IGF-1 binding protein-3 in the setting of increased GH [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Effects of ART on pituitary function</span><span class="headingEndMark"> — </span>The body composition changes associated with ART may affect GH secretion and action, but the specific effects of individual medications on the somatotropic axis have not been determined. (See  <a class="medical medical_review" href="/d/html/3733.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy"</a>.)</p><p>Marked elevations in prolactin levels, accompanied by symptomatic galactorrhea, were reported in four patients treated with protease inhibitors, although three of these patients had received medications known to cause hyperprolactinemia (<a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a> or <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>) [<a href="#rid20">20</a>] (see  <a class="medical medical_review" href="/d/html/6626.html" rel="external">"Causes of hyperprolactinemia"</a>). Use of opioids is also associated with hyperprolactinemia.</p><p class="headingAnchor" id="H8"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Damage to the anterior pituitary can occur suddenly or slowly, can be mild or severe, and can affect the secretion of one, several, or all of its hormones. As a result, the clinical presentation of anterior pituitary hormone deficiencies can vary significantly. The spectrum of clinical manifestations of hypopituitarism is described in a separate topic review. (See  <a class="medical medical_review" href="/d/html/6637.html" rel="external">"Clinical manifestations of hypopituitarism"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Evaluation of pituitary dysfunction</span><span class="headingEndMark"> — </span>When hypopituitarism is suspected, we perform the following initial laboratory tests and have them collected at 8:00 am (due to the diurnal variation in cortisol levels):</p><p class="bulletIndent1"><span class="glyph">●</span>Prolactin</p><p class="bulletIndent1"><span class="glyph">●</span>TSH and Free T4</p><p class="bulletIndent1"><span class="glyph">●</span>Cortisol and ACTH</p><p class="bulletIndent1"><span class="glyph">●</span>IGF-1</p><p class="bulletIndent1"><span class="glyph">●</span>LH and Testosterone (in men)</p><p class="bulletIndent1"><span class="glyph">●</span>FSH, LH, and estradiol (in amenorrheic or oligomenorrheic premenopausal women)</p><p></p><p>TSH alone is inadequate to diagnose secondary hypothyroidism, since it can be low, normal, or even slightly elevated in the setting of a low Free T4. If deficiency of one or more pituitary hormones is confirmed, magnetic resonance imaging (MRI) of the pituitary should be performed. The diagnosis of pituitary dysfunction based on results of these laboratory tests is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6639.html" rel="external">"Diagnostic testing for hypopituitarism"</a>.)</p><p>Regardless of etiology, hypopituitarism is treated with physiologic hormone replacement and requires both biochemical and clinical monitoring of treatment. (See  <a class="medical medical_review" href="/d/html/6640.html" rel="external">"Treatment of hypopituitarism"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">ADRENAL GLAND</span><span class="headingEndMark"> — </span>The major adrenal steroid hormones include the glucocorticoids (particularly cortisol), mineralocorticoids (particularly aldosterone) and androgens, which can also be aromatized to estrogens. Abnormalities in adrenal gland function can lead to electrolyte disturbances, hyper- or hypotension, and changes in sex hormones. (See  <a class="medical medical_review" href="/d/html/120.html" rel="external">"Adrenal steroid biosynthesis"</a>.)</p><p>The effect of HIV infection on adrenal gland function is discussed below.</p><p class="headingAnchor" id="H11"><span class="h2">Alterations in adrenal function</span><span class="headingEndMark"> — </span>Several characteristic alterations in adrenal steroid hormone metabolism have been observed in HIV-infected individuals. These shifts in hormone metabolism may simply signify an adaptive response to systemic illness and often do not require treatment.</p><p>Elevated basal cortisol levels may be accompanied by diminished responsiveness to adrenocorticotropic hormone (ACTH) stimulation [<a href="#rid21">21</a>]. This can lead to an incorrect interpretation of the standard <a class="drug drug_general" data-topicid="9298" href="/d/drug information/9298.html" rel="external">ACTH stimulation test</a> if a "subnormal" increase in cortisol levels is considered diagnostic without taking into account the absolute cortisol levels. (See  <a class="medical medical_review" href="/d/html/157.html" rel="external">"Diagnosis of adrenal insufficiency in adults"</a>.)</p><p>Given that elevated cortisol levels may be present without higher levels of ACTH, non-pituitary factors (eg, cytokines) may be directly promoting adrenal steroidogenesis [<a href="#rid22">22</a>]. Moreover, patients with advanced HIV disease often have an attenuated pituitary-adrenal response to corticotrophin-releasing hormone (CRH) infusion [<a href="#rid23">23</a>].</p><p>Increased ACTH levels may be accompanied by:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased cortisol levels suggesting hypothalamic activation [<a href="#rid24">24</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Low or normal cortisol levels suggesting that the rises in ACTH may be compensatory in the setting of clinical or subclinical adrenal insufficiency</p><p class="bulletIndent1"><span class="glyph">●</span>Paradoxically elevated levels of cortisol despite Addisonian symptoms and signs suggesting peripheral glucocorticoid resistance [<a href="#rid25">25</a>]</p><p></p><p>Since the signs and symptoms of glucocorticoid deficiency are relatively nonspecific and often overlap with manifestations of AIDS, this diagnosis is frequently considered in patients with HIV infection. Prior to the availability of potent antiretroviral therapy (ART), pathologic changes in the adrenal gland were noted commonly at autopsy [<a href="#rid26">26,27</a>]. Depending on the stage of HIV infection, the presence of suggestive clinical signs and symptoms, and the method of diagnostic testing used, the proportion of patients thought to have adrenal insufficiency varied considerably but, in many cases, exceeded 5 percent [<a href="#rid28">28</a>]. Frankly elevated ACTH levels were rarely observed, suggesting that, in those with a subnormal response to ACTH, a secondary (ie, hypothalamic-pituitary) etiology was more likely.</p><p>Although the prevalence appears to be greater than in the general population, clinically significant adrenal insufficiency remains rare in patients with HIV. Overt hormone deficiencies are uncommon given the adrenal gland's high functional reserve; 80 to 90 percent destruction of the adrenal gland is usually required before adrenal failure is clinically apparent. Nevertheless, since untreated adrenal insufficiency has such potentially dire consequences, we recommend evaluation for glucocorticoid deficiency in a patient with AIDS, refractory hypotension, and critical illness. (See  <a class="medical medical_review" href="/d/html/159.html" rel="external">"Clinical manifestations of adrenal insufficiency in adults"</a>.)</p><p>Hyporeninemic hypoaldosteronism, which may present with hyperkalemia, hyponatremia, and metabolic acidosis, was reported in the early AIDS epidemic in a small case series [<a href="#rid29">29</a>]. As originally described in non-HIV infected patients with this condition [<a href="#rid30">30</a>], ACTH-stimulated cortisol levels were normal.</p><p class="headingAnchor" id="H12"><span class="h2">Dehydroepiandrosterone replacement therapy</span><span class="headingEndMark"> — </span>Despite its wide availability and acceptability by HIV-infected patient populations, we suggest <strong>not</strong> routinely using dehydroepiandrosterone (DHEA) until its efficacy and safety have been proven in larger randomized clinical trials.</p><p>DHEA is an adrenal steroid hormone with weak androgenic activity. It has been investigated for its proposed anti-aging and immunomodulatory effects in a variety of clinical settings, including HIV disease. Low DHEA levels and elevated cortisol to DHEA ratios are found in HIV infection, particularly in the setting of body composition changes due to either lipodystrophy or malnutrition. In several cross-sectional studies, low serum concentrations of DHEA have been associated with low CD4 cell counts, weight loss, and progression to AIDS [<a href="#rid31">31-33</a>]. In early in vitro studies, DHEA appeared to inhibit HIV-1 replication and activation in cell culture [<a href="#rid34">34-36</a>]. Clinical trials of DHEA treatment in patients with HIV have found some improvements in quality of life and depression symptoms but no benefit on immune function, metabolism, or body composition [<a href="#rid37">37-39</a>]. These trials were limited by small size and, in one case, lack of blinding.</p><p class="headingAnchor" id="H1561546927"><span class="h2">Effects of medications on adrenal function</span></p><p class="headingAnchor" id="H13"><span class="h3">Antiretroviral drugs</span><span class="headingEndMark"> — </span>ART-associated lipohypertrophy (eg, dorsocervical fat pad enlargement and visceral adiposity) is not associated with overt hypercortisolism, despite phenotypic similarities to Cushing's syndrome [<a href="#rid40">40</a>]. Furthermore, these patients demonstrate normal diurnal cortisol variation and normal cortisol secretory dynamics after administration of ovine CRH [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/3733.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy"</a> and  <a class="medical medical_review" href="/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H1041013381"><span class="h3">Pharmacokinetic boosters with glucocorticoids</span><span class="headingEndMark"> — </span>Exogenous glucocorticoids, given by any route, should be used with caution and carefully monitored among patients using pharmacokinetic boosters. In particular, if a person with HIV has an indication for an inhaled or intra-articular glucocorticoid, we suggest switching to an antiretroviral regimen that does not contain a protease inhibitor or <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>. If changing antiretroviral regimens is not desirable or feasible, because of HIV drug resistance or intolerance to other antiretroviral medications, then <a class="drug drug_general" data-topicid="9068" href="/d/drug information/9068.html" rel="external">beclomethasone</a> is the safest inhaled steroid to coadminister with a protease inhibitor or cobicistat [<a href="#rid42">42</a>].</p><p>Iatrogenic Cushing's syndrome can result from the coadministration of <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> or <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a> and synthetic glucocorticoids, such as nasal or inhaled <a class="drug drug_general" data-topicid="8951" href="/d/drug information/8951.html" rel="external">fluticasone</a>, inhaled <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>, intra-articular <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a>, or topical ocular glucocorticoids [<a href="#rid43">43-51</a>]. The effects of these drugs on cytochrome P450 lead to prolongation of the half-life of the synthetic glucocorticoid. The resultant high plasma levels of glucocorticoid cause features of classic Cushing's syndrome and suppression of endogenous ACTH and cortisol levels (secondary adrenal insufficiency), such that abrupt withdrawal may precipitate an Addisonian crisis. The typical phenotype of Cushing's syndrome may not be recognized when pre-existing ART-associated lipodystrophy is present, given the similarities in clinical presentation (eg, visceral adiposity, peripheral lipoatrophy). In a retrospective study of 171 patients with HIV who received local steroid injections, a surprisingly high risk of subsequent adrenal dysfunction was reported (11 percent of the 81 patients who were also using protease inhibitors) [<a href="#rid52">52</a>]. </p><p class="headingAnchor" id="H1041013389"><span class="h3">Other medications used in patients with HIV</span><span class="headingEndMark"> — </span>Adrenocortical function can be altered by other medications used in the treatment of HIV infection:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a> inhibits adrenal steroidogenesis and can lead to glucocorticoid deficiency in patients with impaired adrenal reserve.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> can lower circulating cortisol levels through enhanced clearance of cortisol.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">Megestrol acetate</a>, a synthetic progestin with intrinsic glucocorticoid-like activity, can suppress both the hypothalamic-pituitary-adrenal and the hypothalamic-pituitary-gonadal axes when administered chronically for appetite stimulation. Long-term exposure can lead to iatrogenic Cushing's syndrome, diabetes mellitus, and Addisonian crisis if the drug is withdrawn abruptly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Opiate use can also be associated with suppression of the hypothalamic-pituitary-adrenocortical (HPA) axis; the subsequent cortisol response to ACTH stimulation may be reduced [<a href="#rid53">53</a>].</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Evaluation and treatment of adrenal dysfunction</span><span class="headingEndMark"> — </span>As in other clinical situations complicated by acute or chronic illness, the optimal method of adrenal functional testing and the normal range for cortisol response are controversial.</p><p>The standard <a class="drug drug_general" data-topicid="9298" href="/d/drug information/9298.html" rel="external">ACTH stimulation test</a> (administration of 250 mcg cosyntropin intramuscularly or intravenously, with cortisol levels checked at baseline, 30 and 60 minutes later) is the most widely available and most frequently performed test. A post-stimulation peak cortisol level greater than 18 to 20 mcg/dL generally excludes adrenal insufficiency. This threshold is based on older serum cortisol assays, and specific monoclonal antibody immunoassays or liquid chromatography-tandem mass spectrometry may have lower thresholds for a normal response (14 to 15 mcg/dL) depending on the assay used [<a href="#rid54">54</a>]. </p><p>Clinicians should note that since the standard stimulation test employs a supraphysiologic dose of ACTH, it is not sensitive in patients with partial or acute pituitary dysfunction. Insulin-induced hypoglycemia or the <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> test are sometimes necessary to confirm the diagnosis of suspected secondary adrenal insufficiency in patients with HIV [<a href="#rid55">55</a>], although these tests are challenging to perform in routine clinical practice. (See  <a class="medical medical_review" href="/d/html/154.html" rel="external">"Determining the etiology of adrenal insufficiency in adults"</a>.)</p><p>Assessment of clinically significant adrenal insufficiency in patients with HIV can be further complicated by hypoalbuminemia since total cortisol levels are typically measured. In a study of 66 critically ill patients, the 36 patients with albumin &lt;2.5 g/dL and subnormal ACTH-stimulated total cortisol concentrations were subsequently found to have normal adrenal function and elevated free cortisol concentrations [<a href="#rid56">56</a>].</p><p>With the above caveats, a standard ACTH test should be performed initially. If this test is normal, but adrenal insufficiency is still suspected, we recommend consultation with an endocrinologist.</p><p>If adrenal insufficiency is confirmed, a baseline ACTH level is useful to distinguish between a primary and secondary etiology:</p><p class="bulletIndent1"><span class="glyph">●</span>A high ACTH level indicates primary adrenal insufficiency, which in a patient with HIV is most often due to an infiltrative process of the adrenal glands, such as tuberculosis, histoplasmosis, or cytomegalovirus adrenalitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A low or normal ACTH level usually implies central adrenal insufficiency. In the latter group, without a known exposure to an exogenous agent that can suppress the HPA axis (eg, glucocorticoids, <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a>), magnetic resonance imaging (MRI) scan of the pituitary should be obtained to exclude an anatomic abnormality. (See  <a class="medical medical_review" href="/d/html/154.html" rel="external">"Determining the etiology of adrenal insufficiency in adults"</a>.)</p><p></p><p>The approach to the treatment of the patient with HIV with glucocorticoid insufficiency is the same as in the HIV-seronegative patient. Glucocorticoid replacement therapy should be initiated using the lowest possible doses (typically <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> 15 to 20 mg/day) that relieve clinical symptoms. Patients with documented adrenal insufficiency require higher doses of glucocorticoids during periods of stress, such as acute illness and/or surgery. The addition of <a class="drug drug_general" data-topicid="8455" href="/d/drug information/8455.html" rel="external">fludrocortisone</a> may be necessary in the setting of primary adrenal failure with concomitant mineralocorticoid deficiency (usually manifested biochemically by hyponatremia, hyperkalemia and metabolic acidosis).</p><p>It is not clear whether patients who have elevated basal cortisol levels with a blunted response to standard ACTH stimulation testing require replacement therapy, since some will respond to prolonged (72-hour) ACTH infusion [<a href="#rid21">21</a>]. These challenging cases must be evaluated individually, taking into account the potential benefits on clinical symptoms and the risks of adverse effects. Some practitioners advocate treating these patients with glucocorticoids only during periods of stress, limiting steroid exposure as much as possible. (See  <a class="medical medical_review" href="/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a>.)</p><p class="headingAnchor" id="H1519501432"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111628.html" rel="external">"Society guideline links: Primary care of adults with HIV"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>In the early AIDS epidemic, endocrine abnormalities were usually due to infiltrative diseases and systemic illness. In the era of potent antiretroviral therapy (ART), there has been a decline in opportunistic infections and malignancies but an increased incidence of metabolic complications, some related to medications. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In general, the diagnosis and treatment of pituitary and adrenal disorders in a patient with HIV infection does not differ from that in an immunocompetent individual. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anterior pituitary functional reserve is usually maintained, whereas posterior pituitary function may be abnormal in a patient with AIDS. (See <a class="local">'Alterations in pituitary function'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The somatotropic axis is influenced by nutritional status and body composition, leading to characteristic abnormalities in patients with AIDS wasting and HIV-associated lipodystrophy syndrome. (See <a class="local">'The somatotropic axis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although the prevalence of glucocorticoid deficiency appears to be greater than in the general population, clinically significant adrenal insufficiency is rare but should be considered in the patient with AIDS, hypotension, and critical illness. (See <a class="local">'Alterations in adrenal function'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low dehydroepiandrosterone (DHEA) levels and elevated cortisol to DHEA ratios are found in HIV infection, particularly in the setting of body composition changes due to either lipodystrophy or malnutrition. We suggest <strong>not</strong> routinely using DHEA replacement therapy in this setting (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The available clinical trials of DHEA replacement therapy in HIV-infected patients are limited, and the efficacy and safety of this therapy remain unproven. (See <a class="local">'Dehydroepiandrosterone replacement therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Certain medications can lead to cortisol insufficiency or excess. Iatrogenic Cushing's syndrome can result from the coadministration of <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> or <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a> and synthetic glucocorticoids (usually inhaled or injected into joints), whereas medications such as <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> can lower circulating cortisol levels through enhanced clearance of cortisol. (See <a class="local">'Effects of medications on adrenal function'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A standard adrenocorticotropic hormone (ACTH) stimulation test should be ordered as the initial approach for evaluation of adrenal function. If adrenal insufficiency is confirmed, an ACTH level should be drawn to help differentiate between primary and secondary adrenal insufficiency. (See <a class="local">'Evaluation and treatment of adrenal dysfunction'</a> above.)</p><p></p><p class="headingAnchor" id="H1029773105"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988; 84:611.</a></li><li><a class="nounderline abstract_t">Raffi F, Brisseau JM, Planchon B, et al. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS 1991; 5:729.</a></li><li><a class="nounderline abstract_t">Hommes MJ, Romijn JA, Endert E, et al. Hypothyroid-like regulation of the pituitary-thyroid axis in stable human immunodeficiency virus infection. Metabolism 1993; 42:556.</a></li><li><a class="nounderline abstract_t">Wilson LD, Truong MP, Barber AR, Aoki TT. Anterior pitutiary and pitutiary-dependent target organ function in men infected with the human immunodeficiency virus. Metabolism 1996; 45:738.</a></li><li><a class="nounderline abstract_t">Poretsky L, Can S, Zumoff B. Testicular dysfunction in human immunodeficiency virus-infected men. Metabolism 1995; 44:946.</a></li><li><a class="nounderline abstract_t">Graef AS, Gonzalez SS, Baca VR, et al. High serum prolactin levels in asymptomatic HIV-infected patients and in patients with acquired immunodeficiency syndrome. Clin Immunol Immunopathol 1994; 72:390.</a></li><li><a class="nounderline abstract_t">Croxson TS, Chapman WE, Miller LK, et al. Changes in the hypothalamic-pituitary-gonadal axis in human immunodeficiency virus-infected homosexual men. J Clin Endocrinol Metab 1989; 68:317.</a></li><li><a class="nounderline abstract_t">Chernow B, Schooley RT, Dracup K, et al. Serum prolactin concentrations in patients with the acquired immunodeficiency syndrome. Crit Care Med 1990; 18:440.</a></li><li><a class="nounderline abstract_t">Gorman JM, Warne PA, Begg MD, et al. Serum prolactin levels in homosexual and bisexual men with HIV infection. Am J Psychiatry 1992; 149:367.</a></li><li><a class="nounderline abstract_t">Collazos J, Ibarra S, Martínez E, Mayo J. Serum prolactin concentrations in patients infected with human immunodeficiency virus. HIV Clin Trials 2002; 3:133.</a></li><li><a class="nounderline abstract_t">Ram S, Acharya S, Fernando JJ, et al. Serum prolactin in human immunodeficiency virus infection. Clin Lab 2004; 50:617.</a></li><li><a class="nounderline abstract_t">Agarwal A, Soni A, Ciechanowsky M, et al. Hyponatremia in patients with the acquired immunodeficiency syndrome. Nephron 1989; 53:317.</a></li><li><a class="nounderline abstract_t">Heijligenberg R, Sauerwein HP, Brabant G, et al. Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1996; 81:4028.</a></li><li><a class="nounderline abstract_t">Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001; 86:504.</a></li><li><a class="nounderline abstract_t">Koutkia P, Canavan B, Breu J, Grinspoon S. Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy. J Clin Endocrinol Metab 2005; 90:32.</a></li><li><a class="nounderline abstract_t">Rochira V, Guaraldi G. Growth hormone deficiency and human immunodeficiency virus. Best Pract Res Clin Endocrinol Metab 2017; 31:91.</a></li><li><a class="nounderline abstract_t">Diazzi C, Brigante G, Ferrannini G, et al. Pituitary growth hormone (GH) secretion is partially rescued in HIV-infected patients with GH deficiency (GHD) compared to hypopituitary patients. Endocrine 2017; 55:885.</a></li><li><a class="nounderline abstract_t">Brigante G, Diazzi C, Ansaloni A, et al. Gender differences in GH response to GHRH+ARG in lipodystrophic patients with HIV: a key role for body fat distribution. Eur J Endocrinol 2014; 170:685.</a></li><li><a class="nounderline abstract_t">Frost RA, Fuhrer J, Steigbigel R, et al. Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. Clin Endocrinol (Oxf) 1996; 44:501.</a></li><li><a class="nounderline abstract_t">Hutchinson J, Murphy M, Harries R, Skinner CJ. Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors. Lancet 2000; 356:1003.</a></li><li><a class="nounderline abstract_t">Membreno L, Irony I, Dere W, et al. Adrenocortical function in acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1987; 65:482.</a></li><li><a class="nounderline abstract_t">Villette JM, Bourin P, Doinel C, et al. Circadian variations in plasma levels of hypophyseal, adrenocortical and testicular hormones in men infected with human immunodeficiency virus. J Clin Endocrinol Metab 1990; 70:572.</a></li><li><a class="nounderline abstract_t">Lortholary O, Christeff N, Casassus P, et al. Hypothalamo-pituitary-adrenal function in human immunodeficiency virus-infected men. J Clin Endocrinol Metab 1996; 81:791.</a></li><li><a class="nounderline abstract_t">Verges B, Chavanet P, Desgres J, et al. Adrenal function in HIV infected patients. Acta Endocrinol (Copenh) 1989; 121:633.</a></li><li><a class="nounderline abstract_t">Mayo J, Collazos J, Martínez E, Ibarra S. Adrenal function in the human immunodeficiency virus-infected patient. Arch Intern Med 2002; 162:1095.</a></li><li><a class="nounderline abstract_t">Bricaire F, Marche C, Zoubi D, et al. Adrenocortical lesions and AIDS. Lancet 1988; 1:881.</a></li><li><a class="nounderline abstract_t">Welch K, Finkbeiner W, Alpers CE, et al. Autopsy findings in the acquired immune deficiency syndrome. JAMA 1984; 252:1152.</a></li><li><a class="nounderline abstract_t">Eledrisi MS, Verghese AC. Adrenal insufficiency in HIV infection: a review and recommendations. Am J Med Sci 2001; 321:137.</a></li><li><a class="nounderline abstract_t">Kalin MF, Poretsky L, Seres DS, Zumoff B. Hyporeninemic hypoaldosteronism associated with acquired immune deficiency syndrome. Am J Med 1987; 82:1035.</a></li><li><a class="nounderline abstract_t">Schambelan M, Stockigt JR, Biglieri EG. Isolated hypoaldosteronism in adults. A renin-deficiency syndrome. N Engl J Med 1972; 287:573.</a></li><li><a class="nounderline abstract_t">Jacobson MA, Fusaro RE, Galmarini M, Lang W. Decreased serum dehydroepiandrosterone is associated with an increased progression of human immunodeficiency virus infection in men with CD4 cell counts of 200-499. J Infect Dis 1991; 164:864.</a></li><li><a class="nounderline abstract_t">Mulder JW, Frissen PH, Krijnen P, et al. Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men. J Infect Dis 1992; 165:413.</a></li><li><a class="nounderline abstract_t">Laudat A, Blum L, Guéchot J, et al. Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: relationship with the CD4 cell counts. Eur J Endocrinol 1995; 133:418.</a></li><li><a class="nounderline abstract_t">Henderson E, Yang JY, Schwartz A. Dehydroepiandrosterone (DHEA) and synthetic DHEA analogs are modest inhibitors of HIV-1 IIIB replication. AIDS Res Hum Retroviruses 1992; 8:625.</a></li><li><a class="nounderline abstract_t">Yang JY, Schwartz A, Henderson EE. Inhibition of HIV-1 latency reactivation by dehydroepiandrosterone (DHEA) and an analog of DHEA. AIDS Res Hum Retroviruses 1993; 9:747.</a></li><li><a class="nounderline abstract_t">Yang JY, Schwartz A, Henderson EE. Inhibition of 3'azido-3'deoxythymidine-resistant HIV-1 infection by dehydroepiandrosterone in vitro. Biochem Biophys Res Commun 1994; 201:1424.</a></li><li><a class="nounderline abstract_t">Piketty C, Jayle D, Leplege A, et al. Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease. Clin Endocrinol (Oxf) 2001; 55:325.</a></li><li><a class="nounderline abstract_t">Abrams DI, Shade SB, Couey P, et al. Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study. AIDS Res Hum Retroviruses 2007; 23:77.</a></li><li><a class="nounderline abstract_t">Rabkin JG, McElhiney MC, Rabkin R, et al. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am J Psychiatry 2006; 163:59.</a></li><li><a class="nounderline abstract_t">Lo JC, Mulligan K, Tai VW, et al. "Buffalo hump" in men with HIV-1 infection. Lancet 1998; 351:867.</a></li><li><a class="nounderline abstract_t">Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999; 84:1925.</a></li><li><a class="nounderline abstract_t">Boyd SD, Hadigan C, McManus M, et al. Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone. J Acquir Immune Defic Syndr 2013; 63:355.</a></li><li><a class="nounderline abstract_t">Samaras K, Pett S, Gowers A, et al. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005; 90:4394.</a></li><li><a class="nounderline abstract_t">Kedem E, Shahar E, Hassoun G, Pollack S. Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. J Asthma 2010; 47:830.</a></li><li><a class="nounderline abstract_t">Gray D, Roux P, Carrihill M, Klein M. Adrenal suppression and Cushing's syndrome secondary to ritonavir and budesonide. S Afr Med J 2010; 100:296.</a></li><li><a class="nounderline abstract_t">Yombi JC, Maiter D, Belkhir L, et al. Iatrogenic Cushing's syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. Clin Rheumatol 2008; 27 Suppl 2:S79.</a></li><li><a class="nounderline abstract_t">Dort K, Padia S, Wispelwey B, Moore CC. Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report. AIDS Res Ther 2009; 6:10.</a></li><li><a class="nounderline abstract_t">Rainsbury PG, Sharp J, Tappin A, et al. Ritonavir and Topical Ocular Corticosteroid Induced Cushing's Syndrome in an Adolescent With HIV-1 Infection. Pediatr Infect Dis J 2017; 36:502.</a></li><li><a class="nounderline abstract_t">Wassner C, Maiti S, Kodroff K, Cohen H. Iatrogenic Adrenal Insufficiency Secondary to Combination Therapy with Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Interlaminar Triamcinolone Injection in an AIDS Patient. J Int Assoc Provid AIDS Care 2017; 16:535.</a></li><li><a class="nounderline abstract_t">Makaram N, Russell CD, Roberts SB, et al. Exogenous steroid-induced hypoadrenalism in a person living with HIV caused by a drug-drug interaction between cobicistat and intrabursal triamcinolone. BMJ Case Rep 2018; 11.</a></li><li><a class="nounderline abstract_t">Elliot ER, Theodoraki A, Jain LR, et al. Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies. Clin Med (Lond) 2016; 16:412.</a></li><li><a class="nounderline abstract_t">Hyle EP, Wood BR, Backman ES, et al. High frequency of hypothalamic-pituitary-adrenal axis dysfunction after local corticosteroid injection in HIV-infected patients on protease inhibitor therapy. J Acquir Immune Defic Syndr 2013; 63:602.</a></li><li><a class="nounderline abstract_t">Cooper OB, Brown TT, Dobs AS. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis 2003; 37 Suppl 2:S132.</a></li><li><a class="nounderline abstract_t">Javorsky BR, Raff H, Carroll TB, et al. New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency after ACTH Stimulation using Specific Cortisol Assays. J Endocr Soc 2021; 5:bvab022.</a></li><li><a class="nounderline abstract_t">Grinspoon SK, Biller BM. Clinical review 62: Laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab 1994; 79:923.</a></li><li><a class="nounderline abstract_t">Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004; 350:1629.</a></li></ol></div><div id="topicVersionRevision">Topic 3720 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3348269" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Endocrine disorders in men infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1883545" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Endocrine function in 98 HIV-infected patients: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8492709" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hypothyroid-like regulation of the pituitary-thyroid axis in stable human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8637449" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Anterior pitutiary and pitutiary-dependent target organ function in men infected with the human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7616856" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Testicular dysfunction in human immunodeficiency virus-infected men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8062450" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : High serum prolactin levels in asymptomatic HIV-infected patients and in patients with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2493026" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Changes in the hypothalamic-pituitary-gonadal axis in human immunodeficiency virus-infected homosexual men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2318055" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Serum prolactin concentrations in patients with the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1346949" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Serum prolactin levels in homosexual and bisexual men with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11976991" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Serum prolactin concentrations in patients infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15481638" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Serum prolactin in human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2601798" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hyponatremia in patients with the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8923855" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158000" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15483073" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28477736" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Growth hormone deficiency and human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27730472" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pituitary growth hormone (GH) secretion is partially rescued in HIV-infected patients with GH deficiency (GHD) compared to hypopituitary patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24536088" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Gender differences in GH response to GHRH+ARG in lipodystrophic patients with HIV: a key role for body fat distribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8762726" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11041407" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3040796" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Adrenocortical function in acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2155251" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Circadian variations in plasma levels of hypophyseal, adrenocortical and testicular hormones in men infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636305" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hypothalamo-pituitary-adrenal function in human immunodeficiency virus-infected men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2555993" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Adrenal function in HIV infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12020177" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adrenal function in the human immunodeficiency virus-infected patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2895383" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Adrenocortical lesions and AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6471338" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Autopsy findings in the acquired immune deficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11217816" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Adrenal insufficiency in HIV infection: a review and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3555065" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hyporeninemic hypoaldosteronism associated with acquired immune deficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4341275" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Isolated hypoaldosteronism in adults. A renin-deficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1682393" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Decreased serum dehydroepiandrosterone is associated with an increased progression of human immunodeficiency virus infection in men with CD4 cell counts of 200-499.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1347053" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7581964" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: relationship with the CD4 cell counts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1381206" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Dehydroepiandrosterone (DHEA) and synthetic DHEA analogs are modest inhibitors of HIV-1 IIIB replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7692906" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Inhibition of HIV-1 latency reactivation by dehydroepiandrosterone (DHEA) and an analog of DHEA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8024587" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Inhibition of 3'azido-3'deoxythymidine-resistant HIV-1 infection by dehydroepiandrosterone in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11589675" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17263636" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16390890" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9525364" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : "Buffalo hump" in men with HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10372688" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23535292" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755851" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20653496" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20460021" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Adrenal suppression and Cushing's syndrome secondary to ritonavir and budesonide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18827959" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Iatrogenic Cushing's syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19505306" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28060049" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ritonavir and Topical Ocular Corticosteroid Induced Cushing's Syndrome in an Adolescent With HIV-1 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28895486" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Iatrogenic Adrenal Insufficiency Secondary to Combination Therapy with Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Interlaminar Triamcinolone Injection in an AIDS Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30567264" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Exogenous steroid-induced hypoadrenalism in a person living with HIV caused by a drug-drug interaction between cobicistat and intrabursal triamcinolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27697800" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23714741" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : High frequency of hypothalamic-pituitary-adrenal axis dysfunction after local corticosteroid injection in HIV-infected patients on protease inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12942387" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33768189" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency after ACTH Stimulation using Specific Cortisol Assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7962298" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinical review 62: Laboratory assessment of adrenal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15084695" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Measurements of serum free cortisol in critically ill patients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
